Table 1. Body weight, right ventricular hypertrophy, and baseline hemodynamic parameters in normal and various stages of PAH rats
NormalSugen5416/hypoxia/normoxia rats
1‐week3‐week5‐week8‐week
BW, g159.5 ± 2.2159.6 ± 5.4237.3± 12.1*298.4 ± 8.4*349.8 ± 19.1*
RV/(LV+S)0.27 ± 0.010.43 ± 0.02*0.48 ± 0.01*0.62 ± 0.02*0.77 ± 0.02*
HR, bpm365.8 ± 10.1342.0 ± 14.0338.6 ± 15.2328.8 ± 8.92317.8 ± 12.5
RVSP, mmHg30.7± 0.657.8 ± 4.8*91.7 ± 9.9*95.8 ± 5.9*128.5 ± 3.8*
CI, mL/min/kg331.5 ± 21.1262.1 ± 19.9247.9 ± 44.0207.3 ± 28.4161.8 ± 23.2*
TPRI, mmHg/(mL/min/kg)0.1 ± 0.010.23 ± 0.030.42 ± 0.06*0.49 ± 0.07*0.86 ± 0.1*
LVSP, mmHg102.3 ± 4.3110.3 ± 7.8122.7± 8.9105.7 ± 7.1123.3 ± 9.4
SVRI, mmHg/(mL/min/kg)0.32 ± 0.030.43 ± 0.050.57 ± 0.090.55 ± 0.080.84 ± 0.11*
  • Baseline data in normal and Sugen5416/hypoxia/normoxia‐exposed rats 1, 3, 5, and 8 weeks after Sugen5416 injection. Values are mean ± SEM, N=5–8 for each group, BW, body weight; RV, right ventricle; LV, left ventricle; S, septum; HR, heart rate; RVSP, right ventricular systolic pressure; CI, cardiac index; TPRI, total pulmonary vascular resistance index; LVSP, left ventricular systolic pressure; SVRI, systemic vascular resistance index. *P < 0.05 versus Normal.